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Summary A complementary DNA library from MCF-7 cells was screened using 32P-cDNA derived from a
breast carcinoma and from normal breast tissue. From 105 plaques (20% of library) we obtained a clone
(Md2) which was differentially expressed in the carcinoma. The distribution of its corresponding transcript of
6-700 nucleotides was examined in normal and neoplastic cells, by filter and in situ hybridisation. We
observed Iocalisation of 35S-Md2 to the tumour cells of breast cancers with no significant reaction over
stromal or vascular elements or on normal ductal epithelia. M13 sequencing showed Md2 to be 250
nucleotides in length, of which 197 were homologous to the 3'-untranslated region and a short open reading
frame of the pS2 gene (Masiakowski et al., 1982). Md2 mRNA was found principally in breast carcinoma cell
lines and tumours, with low levels in benign breast disease and no expression in non-breast squamous cell
lines. Approximately 43% (23/54) ofcarcinomas contained this mRNA (varying from + to + + + +level); it was
present in 20/38 (53%) of ER positive carcinomas compared to 3/16 (19%) of ER negative carcinomas. In 21
patients who had undergone primary endocrine therapy for recurrent disease expression of Md2 in the
primary tumour correlated with the subsequent response to treatment (P=0.041) and was of similar predictive
value as ER status. Both tests correctly predicted outcome in about 76% of cases.
The phenotypic changes which accompany the malignant
transformation of normal cells reflect in all probability an
underlying change in the genotype or of its expression. This
is akin to the induction/repression of regulated genes
(Caplan & Ordahl, 1978) during the differentiation process,
the aberrant expression of which may also lead to the
cancerous state (Wald et al., 1978). Comparisons of the
transcribed genome using differential hybridisation tech-
niques (St John & Davis, 1979) have been used to identify
and isolate several genes that have altered transcriptional
levels associated with human leukaemias (Shiosaka &
Saunders, 1982) and with gastric neoplasms (Shiosaka et al.,
1987). Such studies could also provide clinically useful
diagnostic and prognostic markers which would be of parti-
cular value in very heterogeneous cancers such as those of
the breast. Two-thirds of human mammary carcinomas are
oestrogen receptor (ER) rich and thus ER status has become
a valuable predictor for response to endocrine therapy
(Jensen & DeSombre, 1977), and may have some prognostic
value (Coombes, 1987). However, about half of patients
whose tumours express ER still fail to respond (Osborne et
al., 1980) to anti-oestrogens, and this has prompted a search
for oestrogen responsive elements which could serve as better
indicators. A number of oestrogen-stimulated proteins have
been described, principally using the MCF-7 cell line (Hor-
witz & McGuire, 1978; Butler et al., 1979; Edwards et al.,
1980; Westley & Rochefort, 1980), but none of these have
proved to be as useful as ER status.
More recently, differential hybridisation of MCF-7 cDNA
libraries with reverse transcribed mRNA isolated from hor-
mone treated and untreated cells has resulted in the cloning
of several oestrogen responsive genes (Masiakowski et al.,
1982; Prud'homme et al., 1985; May & Westley, 1986). At
least one of these, the pS2 gene, has been the subject of
intensive study by the same group (Jeltsch et al., 1987;
Nunez et al., 1987; Rio et al., 1987).
Our approach has been to study differential gene expres-
sion in a human cancer, MCF-7, compared to normal breast,
by screening a library of the cancer. Here we describe the
isolation of a differentially expressed clone, Md2 (found to
be homologous to pS2), and its initial characterisation,
including its distribution in breast tissues and cell lines and
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its possible value as a predictor of response to endocrine
therapy.
Materials and methods
Patients
Fifty-four samples were obtained from 53 patients with
breast cancer. Forty-nine were samples obtained at the time
of primary surgery, and five were obtained at the time of
relapse from biopsies of recurrent soft tissue disease. (From
one patient we obtained samples of both primary and
recurrence.) No therapy was given after primary surgery
before the development of recurrent breast cancer. A further
five samples of fibroadenoma were also studied.
Patients' ages ranged from 29 to 85. Of the 49 primary
carcinomas, all but two (one lobular and one colloid carci-
noma) were infiltrating ductal carcinomas and 12 were
associated with ipsilateral lymph node involvement. Forty
per cent of the patients were premenopausal and 60% were
post-menopausal.
Samples were obtained from between 1980 and 1987 and
stored in liquid nitrogen before study. In the intervening
time, 21 patients had relapsed and received primary endo-
crine therapy (tamoxifen 16 cases; aromatise inhibitors five
cases). All had been assessed for response according to
International Union against Cancer criteria (Hayward et al.,
1977). The most common sites of first relapse were bone,
lung, local and liver.
Materials
Tissue culture medium and fetal calf serum (FCS) were
obtained from Gibco (Paisley, UK). Other reagents were
obtained from Sigma Chemical Co. (Poole, Dorset, UK)
unless stated.
Cell culture
Human breast carcinoma cell lines (Engel & Young, 1978)
and human squamous carcinoma cell lines (Easty et al.,
1981) were used in this study. Breast cell lines were MCF-7
(two sources of this line were used: Dr M. Lippman, NCI,
Bethesda, MD, USA, and the laboratory of origin, the
Michigan Cancer Foundation), T47D (Dr H. Freake,
Hammersmith Hospital, London, UK), MDA-MB-231
(Mason Research Institute, Rockville, MD, USA), ZR-75-1
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(Dr M. Lippman). Squamous cell lines were LICR-LON-
HN-I,-5,-6 and -7 (Professor B. Gusterson, Institute of
Cancer Research, Sutton, Surrey, UK). All cell lines were
maintained in DMEM with 10% FCS and penicillin/strepto-
mycin except for MCF-7 from Dr M. Lippman, which were
maintained in similar medium supplemented with 10pgml-1
insulin, 10-8M oestradiol and non-essential amino acids.
Preparation of human breast organoids
Organoids (Stampfer et al., 1980) were prepared from reduc-
tion mammoplasty tissue. Briefly, the attached skin and
excess fat were removed and the residual tissue was finely
diced and digested at 37°C for 18-22h with collagenase
(Type IA, at 0.5mgml-1) in DMEM with 7% FCS, 10mM
Hepes and antibiotics. Epithelial tissue fragments were pel-
leted by centrifugation at 1,000g for 5min, then resuspended
in fresh medium without collagenase and allowed to settle
for 18 h at 4°C. After a further digestion of 2h at 37°C with
2.5mgml-1 collagenase, the organoids were recovered by
repeated gravity sedimentation for 20-60min at 4°C. Viabi-
lity was estimated by trypan blue exclusion.
Some preparations were examined for breast morphology
and the presence of contaminating blood vessels by immuno-
cytochemistry. Monoclonal antibody LICR-LON-59.2, which
recognises a cell surface component of myoepithelial cells,
plus blood vessels in the human breast (R. Skilton et al.,
unpublished), was used to stain frozen sections of organoid
preparations by the immunoperoxidase technique (Gusterson
et al., 1985). Organoids were stored under liquid nitrogen.
cDNA library
A human breast carcinoma cell line (MCF-7) random
primed cDNA library in Agtll 1, consisting of 5 x 105 clones,
was kindly provided by Professor P. Chambon (Institut
Chimie Biologie, Strasbourg, France).
RNA extraction
Poly(A)+RNA was extracted from 200-5001 of packed
MCF-7 cells and organoids by lysis with 7ml proteinase K
buffer (300ygml-1 proteinase K, 2% SDS, 10mM vanadyl
ribonucleoside complex (Gibco-BRL), 0.2 M NaCl, 1.5mM
MgCl2, 0.2M Tris/HCl, pH7.5), and incubation at'45°C for
2h. During the incubation the lysates were passed several
times through a 0.6mm diameter syringe needle to shear the
DNA.
Lysates were cleared by centrifugation at 10,000g for
10min and poly(A)+RNA was extracted by affinity
chromatography on oligo (dT)-cellulose (Maniatis et al.,
1982). Its quality was checked by ability to produce trans-
lation products in vitro using the rabbit reticulocyte lysate
system (Amersham Int. plc) in the presence of 14C-
methionine (Amersham Int. plc) according to published
methods (Davis et al., 1986), and labelled products were
analysed by polyacrylamide gel electrophoresis (10% PAGE/
SDS gels) (Laemmli, 1970).
All other RNA used in this study was extracted from cells
and biopsy material by the guanidine isothiocyanate method
(Chirgwin et al., 1979). The quality of this RNA quantified
spectrophotometrically was verified by the integrity of the 28
and 18S ribosomal bands following agarose gel electro-
phoresis.
Screening
About 105 clones from an MCF-7 cDNA library were
screened using standard methods. Filters (Hybond N,
Amersham, UK) were prehybridised at 42°C for 4-20h in
50% (v/v) deionised formamide (Rose Chemicals, London,
UK), 0.1% (w/v) SDS, 5 x Denhardt's solution (50 x Den-
hardt's solution: 1% (w/v) each of polyvinylpyrrolidine,
bovine serum albumin and Ficoll 400), 5 x SSPE (20 x SSPE:
0.02M EDTA, 3 M NaCl and 0.2M NaH2PO4, pH8.3) and
denatured sonicated salmon sperm DNA (250pgml-1).
Duplicate filters were then hybridised under the above
conditions for 18h with the addition of 4 x 106 c.p.m.ml-1
32P-cDNA, prepared from MCF-7 or organoid
poly(A)+RNA by oligo dT primed reverse transcription
(Huynh et al., 1985). Following hybridisation, filters were
washed with five changes of 2 x SSC, 0.1% SDS at 25°C,
and two changes of 0.2 x SSC, 0.1% SDS at 55-60°C.
Subeloning into pBr322
cDNA inserts from Agtl1 phage DNA were excised with
EcoRl, ligated into pBR322 plasmid (Biolabs) in the EcoRl
site, and transformed in E. coli JM109. Plasmid DNA was
isolated by the alkaline lysis method (Birnboim & Doly,
1979), and insert was removed by EcoRl digestion, purified
by preparative agarose gel electrophoresis, and labelled with
32p or 35S-dCTP (Amersham) by the random primer method
(Feinberg & Vogelstein, 1983) to specific activities of
109c.p.m. pg- and 1.5 x 108c.p.m. pg- DNA respectively.
DNA sequencing
The Md2 cDNA was excised from Agtl1 phage DNA with
EcoRl and inserted into the M13 vectors mp8 and mp9.
Single stranded templates were prepared from recombinant
plaques and subjected to dideoxy chain termination
sequencing (Vieira & Messing, 1982).
Dot blot hybridisation and Northern analysis
As most biopsies were small and the RNA extracted was
generally low, hybridisation was normally performed using
total rather than poly(A)+RNA. Wherever possible dot blots
were done using serial dilutions of formaldehyde or glyoxal
denatured RNA ranging from 10-20 pg to 1.25pg, spotted
on to Biodyne A nylon membrane (Pall Filtration,
Portsmouth, UK) using a Bio-dot manifold (Bio-Rad, UK).
Northern analysis of total RNA (20pg per lane) or
poly(A)+RNA (2.5pg per lane) was carried out following
transfer from agarose/formaldehyde gels (Seed, 1982). Tran-
scripts were sized using denatured RNA and DNA
markers. Hybridisation was carried out as described for
library screening above, except 32P-labelled Md2 cDNA at
0.5-1.0 x 107 c.p.m. ml- was employed as the probe, and
filters were washed to a higher stringency (0.1 x SSC, 0.1%
SDS at 60-65°C).
The autoradiograms were quantified by comparison with
an Md2 standard and dots were given a value ranging from
0 (undetectable), ±+ (just detectable above background) to
+ + + +. The highest intensity represents 100pg of hybridis-
able message per 20pg total RNA.
DNA preparation and Southern blotting
Tumour samples and cells, stored in liquid nitrogen, were
thawed to 25°C in 5 volumes of 10mM NaCI, 1 mM EDTA,
10mM Tris pH8, and disrupted with a polytron. Sarkosyl,
0.1 volumes of 10% (w/v) solution, and proteinase K (to
200upgml-1) were then added and the homogenate incu-
bated, with agitation, at 25°C for 2h. The solution was
extracted twice with an equal volume of phenol (saturated
with 1 M Tris pH8) and twice with an equal volume of
chloroform-isoamyl alcohol (24:1) and the DNA precipi-
tated with ammonium acetate and isopropanol dissolved in
5-lOml TE (10mM Tris, lmM EDTA, pH7.5) and re-
precipitated with ethanol. The DNA was then dissolved in
10mM TE and digested in 10pg aliquots for 24h with 80u
EcoR1 or 60u HindIII or BamHI (NBL), ethanol precipi-
tated, electrophoresed in 0.8% agarose gels (Maniatis et al.,
1982) and transferred to Biodyne A nylon membranes
(Southern, 1975). Hybridisation of Southern filters were
carried out essentially as described above, using 32P-labelled
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In situ hybridisation
The procedure was a modification of that described by
Barrett-Lee et al. (1987) after Lawrence & Singer (1985).
Frozen sections (5-7,m) fixed in 4% paraformaldehyde in
PBS, 5mM MgC12 for 15min and stored in 70% ethanol at
4°C, were rehydrated in PBS, 5mM MgCl2 for 10min at
25°C, incubated with 50pgml-1 pronase in PBS, 5mM
MgC12 for 10min at 25°C and briefly post-fixed (4%
paraformaldehyde in PBS, 5mM MgCl2) for 5min. To
reduce non-specific adherence of probe, sections were
immersed in 0.1 M triethanolamine buffer containing 0.25%
(v/v) acetic anhydride for 10min at 25°C. Slides were then
transferred to 0.1 M glycine, 0.2M Tris pH 7.4 for 10min and
then into 50% formamide, 2 x SSC at 65°C for 15min.
Sections were hybridised to denatured random primed 35S-
labelled Md2 cDNA (specific activity 1.5x 108c.p.m. ug-1)
containing in a total volume of 10pl, 10Mg of each of E. coli
tRNA and sonicated salmon sperm DNA, 50% formamide
2 x SSC, 2mgml-1 bovine serum albumin, 20mM dithioth-
reitol, 10% dextran sulphate, 0.1 x Denhardts at 37°C for
4h. Following extensive washing sections were sequentially
dehydrated in 70, 80, 95 and 100% ethanol and air dried.
For cell lines, cells were grown on gelatin coated glass
slides, fixed and treated as for tissue sections. In all experi-
ments, parallel incubations were performed using labelled
pUC8 fragments as a nonspecific probe. Autoradiography
was carried out using a 50% aqueous solution of K5 nuclear
emulsion (Ilford Ltd, UK) at 43°C, followed by exposure for
4-10 days at 4°C. Counter staining was with Haematoxylin
and Eosin.
Oestrogen receptor measurement
This was carried out using either the ligand binding dextran
coated charcoal (DCC) technique (McGuire & De La Garza,
1973), with modifications outlined by McClelland et al.
(1986); or by an immunocytochemical assay (ERICA) using
the H222 monoclonal antibody kit (Abbott Laboratories,
Chicago, USA). The staining procedure has been described
in detail elsewhere (McClelland et al., 1986).
Results
Organoids
The viability of organoids estimated by trypan blue exclusion
was greater than 80% in all preparations. Frozen sections
were taken from some preparations and stained for myoepi-
thelial cells and blood vessels by immunoperoxidase using
the monoclonal antibody LICR-LON-59.2. The organoids in
these sections showed well preserved morphology with intact
layers of myoepithelial and epithelial cells similar to breast in
situ (Figure 1). From the sections examined it was estimated
that blood vessels constituted less than 5% of the tissue in
the organoid preparations.
Products from the in vitro translation of organoid
poly(A) +RNA were analysed by SDS-PAGE alongside those
from MCF-7. Both showed numerous polypeptides (many in
common) as discrete bands up to about 90kD and more
weakly staining bands at higher molecular sizes (data not
shown). Thus the poly(A) +RNA from both MCF-7 and
organoids were of comparable quality.
Differential screening
A screen involving about 20% of the phage from the Agtl1
MCF-7 cDNA library yielded six clones which showed
differential hybridisation to 32P-cDNA made from
poly(A)+RNA of normal breast organoids or MCF-7 cells.
One of these, designated Md2, gave a very strong signal with
32P-MCF-7 cDNA but none with 32P-organoid cDNA. The
cloned Md2 Agtl 1 phage was subjected to a differential
screen with cDNA derivecd from mRNA of MCF-7 and
Figure 1 Normal breast organoids stained by monoclonal anti-
body LICR-LON-59.2. Frozen sections of organoid pellets were
:~ 3> ... . . :: -'R.:::~ ~' i . ; r
~ :
cut at a thickness of 6pm, air dried for 2 h and fixed in acetone.......
for 5em at 4NC. The immunoperoxidase staining procedure
followed published procedures (Gusterson et al., 1985). The
myoepithelial cells of ducts and lobular alveoli units were stained
with this antibody whereas the epithelial cells lining the lumen
were unstained. Most of the cells in organoid preparations as
shown here were organised into duct-like structures similar to
those of whole tissue sections (original magnification: x 120).
organoids of different sources to those used in the primary
screen, with the same result. The Md2 cDNA insert was
subcloned into pBR322, and found to hybridise to about
0.067% of the clones in the library, suggesting a highly
represented sequence.
Size of Md2 mRNA
Northern blot analysis of MCF-7 mRNA indicated hybridis-
ation of the Md2 cDNA corresponding to a major mRNA
species of approximately 0.6-0.7kb (Figure 2). Sometimes a
faint band of about 3kb could be seen with MCF-7 cells
with very much longer exposures. We also saw this using
pS2 clone. No signal was seen with a primary breast ER
negative carcinoma, a fibroadenoma and MDA-MB-231
cells.
Southern analysis
Southern blotting analysis with 32P-Md2 cDNA was per-
formed on DNA from cell lines and breast tumours digested
with EcoRl (Figure 3), BamHl and Hindlll. This yielded
discrete bands of 3.1 and 9.0kb for EcoRl, 3.5 and 7.9kb
for BamHI and 4.9kb and >21 kb for Hindlll (data not
shown). No difference was observed between Md2 mRNA
positive and negative tumours. We also found bands of
5.9kb and 2.1 kb for EcoRl digested DNA of MCF7, which
could also be seen as very faint bands in the tracks of breast
cell lines ZR-75-1, MDA-MB-231 and T47D, and an orga-
noid preparation.
Sequence analysis of Md2 clone
The Md2 cDNA was sequence using the dideoxy chain
termination technique. Figure 4 shows the nucleotide
sequence between the EcoRI linker insertion sites. There is a
short open reading frame with a termination codon. Com-
parison of this sequence with that of pS2 (Jakowlew et al.,
1984) showed complete homology for nucleotides 54-249
(Figure 4) with only two differences (underlined), one of
which has also been reported by Prud'homme et al. (1985).
Thus most of the Md2 corresponds to the 31-untranslated
region of pS2 mRNA. Nucleotides 1-53 are unrelated to
pS2, and we can only surmise that this sequence became
attached to the remainder, during the linker ligation to blunt
ended cDNA in the construction of the library.DIFFERENTIALLY EXPRESSED mRNA IN HUMAN BREAST 171
1 2 3 4 I ·o 20 30 40 50
GGAATTCCATCACCTTGTTCTCCATGGTGGCCATTGCCTCCTCTCTGCTCCAAAGGCGAC CCT CCA
PRO PRO
60 70 80 90 100 110
GAA GAG GAG TGT GAA TTT [¥A-1 ACACTTCTGCAGGGATCTGCCTGCATCCTGACG
GLU GLU GLU CYS GLU PHlE
.......... :* 120 130 140 150 160 170 180
~~~~~' ~~~~~~~CGGrGCCGTCCCCAGCACGGTGATTAGTCCCAGAGCTCGGCTGCCACCTCCACCGGACACCTCAGACACGCTTC
190 200 210 220 230 240 * 250
i~i~,~i .iia~ TGCAGCTGTGCCTCGGCTCACAACACAGATTGACTGCTCTGACTTTGACTACTCAAAAATGGGGAATTC
Figure 4 Nucleotide sequence of Md2 determined by the
dideoxy chain termination technique (Vieira et al., 1982).
........ . ..........Number excludes the EcoRI linkers. A short open reading frame
:~;::,'iiig(::ii:i is indicated. Sequence homology to pS2 (Jakowlew et al., 1984) .%:':,'~:L[':~i;~ !i~ extends from position 54-249 except for two differences which
are marked by an asterisk. The stop codon is boxed.
Hi ~~4.7
~~~~~.:.<:.. ..:! ~'... :.::5 27. T47D and MDA-MB-231. However, pS2 mRNA was
..........expressed in ZR-75-1 breast tumour line at a level similar to
that found in MCF-7. We also found a high level (+ + +) of
expression in a single case of an abdominal metastases from 1.4 an ovarian carcinoma.
In situ hybridisation
Specific localisation was observed in breast cancer cell lines
MCF-7 and ZR-75-1 (Figure 6a-d) The autoradiographic
grains were found to be distributed over the peripheral
cytoplasm and the cells were clearly heterogeneous with
respect to grain density. Such heterogeneity of expression is
::'::?ii!,:.'......................o.....often seen in breast tissue and cell line samples with ERICA
staining. T47D and MDA-MB-231 cells showed little or no
Figure 2 Northern blot analysis. Total RNA (20#g) was
formaldehyde denatured, electrophoresed in a formaldehyde 1 2 3 4
agarose gel and blotted on to Biodyne A nylon membranes and -K
hybridised with 32P-Md2 cDNA probe. After washing, the filter :
was exposed to Hyperfilm (Amersham) for three days. The
source of the RNA was: (1) primary breast carcinoma; (2) MCF-
7; (3) fibroadenoma; (4) MDA-MB-231. Sizes of DNA markers -:.,:: ,,:i,.**~
are shown in kb. The single intense band corresponds to an ~i;iI?i1
mRNA size of 600-700 bases..-
EcoRl :.
1 2 3 4 5 6 7 8 9 1011 121314 1516
::'...:' -': ...x':
....... -'........;:~*'..
. ......
3.1~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~I
Figure 3 Southern blot analysis of genomic DNA with 32P-Md2
cDNA. About I0jg of DNA were digested with EcoRI, electro-
phoresed in an 0.8% agarose gel, blotted on to Biodyne nylon
filter and hybridised with 32P-Md2 cDNA. Sizes of hybridising
species are indicated. The varying intensities are due to different
amounts loaded on to the gel and are not significant. DNA in
lanes 1, 7, breast organoids; 2, 9, 10, 12-16, primary breast
carcinomas; 3, T47D; 4, MCF7; 5, ZR-75-1'6, MDA-MB-231'8,
11, lymph node metastases. ii
pS2 mRNA in cell lines and non-malignant tissues .· .
Md2/pS2 mRNA was undetectable by dot blot hybridisation
in three organoid preparations. We found only low levels (+)
of pS2 message in 4/5 (80%) biopsies histologically identified Figure 5 Northern blot of RNA from fibroadenomas,
as fibroadenomas. This is illustrated in Figure 5. It was not hybridised to 32p-Md2 cDNA. Experimental details as in legend expressed in normal lymphocytes, placenta, colon, skin, to Figure 2 Lanes 2-4 had 20 g RNA from three different
squamous carcinoma cell lines of various tissue origins fibroadenoma samples. Lane 1 had 4#.tg MCF-7 RNA for
(tongue, larynx, bronchus) or in breast tumour cell lines companson.172 R.A. SKILTON et al.
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Figure 6 Demonstration of Md2 mRNA in cultured cells by in situ hybridisation. Breast carcinoma cells were hybridised with
35S-labelled Md2 (a,c,d) or with pUC8 (b). a, ZR-75-1 breast carcinoma cells (ER positive) showing hybridisation of Md2
predominantly to cytoplasmic component of cells. Weak non-specific binding to glass is also visible (original magnification x 870).
b, ZR-75-1 breast carcinoma cells hybridised with pUC8 showing as non-specific hybridisation for comparison with a (original
magnification x 870). c, MDA-MB-231 breast carcinoma cells (ER negative) showing levels of hybridisation comparable only with
non-specific controls (original magnification x 600). d, MCF-7 breast carcinoma cells (ER positive) showing high levels of
expression of Md2 mRNA. Marked heterogeneity of expression is reflected in the varied grain densities shown in the cytoplasm of
these cells (original magnification x 870). Hybridisation was carried out using 35S-labelled probes of comparable specific activity
at 37°C for 4h; autoradiography was 3-4 days. Cells were counterstained in Mayer's Haematoxylin to highlight cell nuclei.
specific hybridisation with Md2 when compared with
controls.
Hybridisation of Md2 was also visualised in a number of
cases of ER positive breast carcinoma (Figure 7). We found
good agreement between this method and measurement
using filter hybridisation. Specific hybridisation to the
tumour cell component of the sections was noted while only
background levels were observed in the stromal tissue. Ducts
of histologically normal appearance in tumour sections did
not show any significant reactivity.
Distribution ofpS2 mRNA in breast tumours: comparison with
oestrogen receptor
We examined pS2 expression (Figure 8) in a total of 54
tumours (49 primaries and five secondaries) by dot blot
hybridisation, and found varying levels of message (+ to
+ + + +)clearly detectable above background signal seen with
poly A-RNA in 23 cases (43%). In four other cases very
low (±) levels of pS2 were observed. Only 1/5 secondary
carcinomas was positive (+).
The ER status of the tumours was determined by ERICA
in all but eight cases (which had previously been assayed by
the DCC method) and compared with pS2 expression. The
results are shown in Table I; 38 (70%) were ER +ve and 16
(30%) ER -ve which agrees well with previous data on this
distribution. In the ER +ve group 20/38 (53%) were pS2 +ve
(+level or more), whereas in the ER -ve cancers 3/16 (19%)
were pS2 +ve. All these were primary infiltrating ductal
carcinomas. There was no difference in Md2 hybridisation
Table I Relationship of oestrogen receptor content to pS2 status in
54 breast cancer biopsies
Md2 hybridisation levela
ER status 0 + + ++
Positive
Negative
16 2 7 5 4
11 2 1 1 1
+++ ++++
4
aDetermined as described under Methods.
between pre- and post-menopausal patients, with 47% and
54% positivity, respectively. Nodal involvement was also
uncorrelated.
From one patient we assayed both the primary tumour
and a local recurrence obtained after tamoxifen and
medroxyprogesterone acetate treatment. While both had ER
+ve cells, only the primary expressed pS2 (+level).
In order to determine whether there was any correlation
between pS2 expression in the primary tumour compared to
ER status and the response of the patient to endocrine
therapy, we performed the following analysis for 21 patients:
for ER, a cut off point was taken of > 15 fmolmg- 1 cytosol
protein (DCC method) or >50% of cells stained (using
ERICA) for assessment of positivity. For Md2, the cut off
point was + or below. Outcome of therapy was assessed
using UICC criteria (Hayward et al., 1977). The time to first
relapse ranged from 8 months to 6 years with a median
value of 36 months.
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Figure 7 Demonstration of Md2 mRNA in frozen tissue sections by in situ hybridisation. Breast carcinoma cells were hybridised
with Md2 (a,c) or with pUC8 (b,d). a, Infiltrating ductal carcinoma (ER positive) showing hybridisation of Md2 to tumour cells.
Weaker grain density is found over stromal areas of section (original magnification x430). b, pUC8 control section of same
tumour as shown in a giving representation of comparative levels on non-specific probe hybridisation (original magnification
x430). c, Intraductal component of a breast carcinoma (ER positive) showing strong Md2 expression by tumour cells within
ductal unit. Surrounding stroma remains relatively free of hybridised probe (original magnification x220). d, pUC8 control
section of same tumour as shown in c (original magnification x 220). Hybridisation in all cases was carried out with 35S-labelled
probes of comparable specific activity at 37°C for 4h; autoradiography was for 3-4 days. Sections were counterstained in Mayer's
Haematoxylin and Eosin.
1 2 3 4 5 6 7 8 9 10 11 12
Figure 8 Dot blot analysis of total RNA from several breast
cancers showing hybridisation of 32P-labelled Md2 to serially
diluted (10, 5, 1#g) aliquots of each sample. Poly(A)-RNA was
applied in lane 1, to assess the extent of non-specific hybridisa-
tion. Lanes 2-9 and 12 are primary breast cancer biopsies, lane
10 is MDA-MB-231 and lane 11 is MCF-7.
The results shown in Table II demonstrate that pS2
expression could correctly predict outcome of therapy in
76% of the patients (P=0.041; Fisher's exact test (one-
tailed)), compared with 75% for ER. There did not appear
to be any greater benefit in adding both predictors.
Discussion
We adopted the method of differential hybridisation (St
John & Davis, 1979) in a search for differences in gene
expression between normal and malignant breast, which
could result in isolation of clones that may have clinical
Table II Relationship of pS2 expression and oestrogen receptor expression to response to endocrine therapy
Outcome of endocrine therapy
Md2
or Complete or Stable Progressive Correct
ER status partial responsea disease disease predictionb
Md2 0/±/+ 3 2 11
Md2 ++/+ + +/+ + + + 3 0 216/21 (76%)
ER negative 1 1 10
ER positive 4 1 15/20 (75%)
aER was not determined in one of the six patients in this group.
bThe hypothesis being that the presence of the marker will be associated with successful therapy.
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value as prognostic indicators. When compared by in vitro
translation, mRNA from MCF-7 and organoids gave very
similar products, and the differential screens also suggest
that the two mRNA populations are very similar in the
abundant to mid-abundance class. From a screen of about
105 plaques of an amplified Agtl 1 MCF-7 library (equivalent
to 20% of the original number of recombinants) we detected
only six major differences, and have reported results with
one of these clones, Md2.
Other groups have used differential screening of cDNA
libraries to clone specifically oestrogen regulated genes
(Masiakowski et al., 1982; Prud'homme et al., 1985; May &
Westley, 1986) and progestin regulated genes in breast cancer
(Chalbos et al., 1986). One oestrogen regulated sequence first
isolated by Masiakowski et al. (1982), subsequently by
Prud'homme et al. (1985) and probably also by May &
Westley (1986) is the pS2 gene. Sequence analysis of the
Md2 clone showed that it essentially encoded most of the 3'-
untranslated region homologous to pS2.
The pS2 gene is reported to be expressed predominantly in
ER positive breast cancers (97% of pS2 mRNA positive
cancers being ER positive (Rio et al., 1987)). We found it to
be significantly expressed in 3/16 (19%) ER negative
tumours. Also pS2 mRNA has been reported as undetectable
in benign breast tumours (Rio et al., 1987) whereas we found
Md2 hybridisation, albeit at low levels in 4/5 fibroadenomas.
These differences are probably due to the higher specific
activity (109 c.p.m. g-') of our probes (compared to
108c.p.m. ig-' (Rio et al., 1987)). Md2 hybridisation was
also found in an ovarian carcinoma (data not shown). It is
possible that the patient whose primary tumour but not the
recurrence expressed Md2 (although ER status had remained
unchanged) did so as a result of the tamoxifen therapy.
Recently Rio et al. (1988) reported pS2 expression in normal
human stomach, which we have also found (Bennett et al.,
1989). They were unable to detect pS2 in any other normal
tissue except salivary gland.
Southern blotting analysis of the Md2/pS2 gene using
DNA from Md2 mRNA positive and negative breast
tumours, digested with EcoR1 (Figure 3), BamHl and
Hindl 11l gave similar results for Md2 positive and negative
tumours. This indicates that the lack of Md2 expression is
not due to an absence of the gene; similarly high pS2
expression is not due to gene amplification. The slight
differences in the intensities shown in Figure 3 were due to
differences in loading as judged by the ethidium bromide
staining before transfer.
The banding pattern was very similar to that reported for
the pS2 gene (Jeltsch et al., 1987). Results with BamHl and
Hindl 11 digested DNA were similar to those seen using pS2
but the Md2 also revealed additional fragments, namely a
4.9kb Hindl 11 fragment and 7.9kb BamH1 fragment. There
were also two extra EcoRI bands in the MCF-7 track
(Figure 3), which could be seen as very faint bands in the
tracks of the other breast cell lines and an organoid pre-
paration but not in any tumour. The significance of these
additional bands, which were not reported for pS2, remains
to be seen. They could be ascribed to hybridisation by
nucleotides 1-53 of Md2. However, this portion does not
contribute to the RNA hybridisation as only the pS2 mRNA
band was observed.
As reported previously (Barrett-Lee et al., 1987) we found
that results obtained using in situ hybridisation correlate well
with the filter hybridisation method. We were able to
observe good localisation of Md2 to cancer cells. It was not
clear whether myoepithelial cells, which can still be seen in
intraductal carcinomas, expressed Md2 to the same extent as
the epithelial cancer cells, but no significant reaction was
seen in the stromal tissue or vascular elements. This tech-
nique will prove very useful in our intended studies of Md2
(and other clones) in needle aspirates, in which we hope to
measure expression throughout the course of endocrine
therapy.
The value of ER status in predicting response to endocrine
therapy (Coombes, 1987) has been evident for some time.
Here, we have shown that Md2 may be an equally reliable
predictor of response. Like ER, its expression was signi-
ficantly related to outcome of therapy. It should also be
noted that of the three responders who were put into the
Md2 'negative' category (refer to Table II) only one had a
zero level for Md2. Therefore it may be that a re-assessment
of our cut-off point for Md2 will improve its predictive
value. In view of its relative abundance (and hence ease of
detection) compared to ER this mRNA could prove to be a
valuable marker. As with most analyses of this kind it is
important to keep sample numbers in perspective. We hope
to obtain more clinical data from patients presently under-
going primary endocrine therapy to provide a larger group
for statistical analysis, before coming to any firm conclusions
on the usefulness of pS2 as a clinical marker.
We thank Professor P. Chambon for the MCF7 cDNA library and
pS2 probe, Dr A. McLeod for the sequencing, Priti Shah for help
with the organoid preparations, Drs P. Barrett-Lee and M. Travers
for preparation of some of the tumour RNA samples and Alison
Lundie and Helen Taylor for typing the manuscript.
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